Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

Biotechnology

Healthcare
$7.38 -2.78%

-$0.15 today

Market cap
$2.10B
Beta
0.71
P/E (TTM)
-7.1
EPS (TTM)
-$0.71
52W Low $1.99High $5.32

Volume 1.41M

Average 2.42M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$57.57M

FY 2025 · Annual

Investing Cash Flow

-$31.41M

FY 2025 · Annual

Financing Cash Flow

-$16.50M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income469.25M490.66M(119.03M)(259.62M)(130.77M)
Depreciation & Amortization24.75M38.1M48.78M56.87M60.47M
Deferred Income Tax46.9M42.32M754.94M2.32M(20K)
Stock-Based Compensation10.46M18.67M34.59M49.42M0
Change in Working Capital(176.63M)(45.08M)97.84M(12.61M)(7.98M)
Accounts Receivables(70.39M)(22.27M)84.4M14.36M12.82M
Inventory(21.57M)9.46M649K377K8M
Accounts Payables676K(1.58M)5.28M723K(7.35M)
Other Working Capital(85.34M)(30.69M)7.52M(28.07M)(21.45M)
Other Non-Cash Items(6.16M)(8.7M)(690.9M)171.1M20.73M
Operating Cash Flow368.57M535.98M126.22M7.47M(57.57M)
Capital Expenditures(14.85M)(17.09M)(65.55M)(29.66M)(13.15M)
Acquisitions (Net)119.96M(238.35M)(69.62M)0(18.26M)
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities548K(12.17M)12.87M5.34M0
Investing Cash Flow105.66M(267.61M)(122.31M)(24.32M)(31.41M)
Debt Repayment(6M)(5.44M)(5.77M)(234.07M)(5.44M)
Common Stock Issued1.71M2.36M000
Common Stock Repurchased00(20K)(2.08M)0
Dividends Paid00000
Other Financing Activities(154.76M)(184.42M)(55.3M)443K(11.06M)
Financing Cash Flow(159.05M)(187.5M)(61.09M)(235.71M)(16.5M)
Effect of Forex Changes(88K)000(32K)
Net Change in Cash315.09M80.87M(57.18M)(252.56M)(105.51M)
Free Cash Flow353.72M518.89M60.67M(22.19M)(70.72M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$130.8M
+ D&A$60.5M
+ Stock-Based Comp$0
- Deferred Tax-$20.0K
- Working Capital-$8.0M
+ Other Non-Cash$20.7M
= Operating Cash Flow-$57.6M
- Capex-$13.1M
= Free Cash Flow-$70.7M

Analysis

FY2025 free cash flow is -$70.7M. FCF conversion is 54.1% of net income. Operating cash flow was -$57.6M, with capex of -$13.1M. The largest bridge item is D&A at $60.5M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 4, 2026
4Statement of changes in beneficial ownershipNov 2, 2026
4Statement of changes in beneficial ownershipOct 9, 2026

Does MRVI generate free cash flow?

Maravai LifeSciences Holdings, Inc. (MRVI) generated -$70.72M of free cash flow in fiscal 2025.

How much operating cash flow does MRVI produce?

Operating cash flow was -$57.57M, before capital expenditures of $13.15M.